

## DAFTAR PUSTAKA

1. Unaid.org (2021,02 Februari). Global HIV and AIDS statistics : 2020 fact sheet. Diakses pada 02 Februari 2021, dari <http://unaid.org/en/resources/fact-sheet>
2. Infodatin Situasi Penyakit HIV AIDS di Indonesia, Pusdatin, Kementerian Kesehatan, 2020
3. Beyrer C, Pozniak A. HIV drug resistance-an emerging threat to epidemic control. *N Eng J Med*. 2017;377(17):1605–07
4. Clutter DS, Jordan MR, Bertagnilo S, Shafer R. HIV drug resistance and resistance testing. *Infect Genet Evol*. 2016;46:1302–07
5. Kementerian Kesehatan Republik Indonesia (Kemenkes RI) : Peraturan menteri Kesehatan Republik Indonesia Nomor 87 Tahun 2014 tentang Pedoman Pengobatan Antiretroviral. 2019.
6. Kusumaningrum A, Ibrahim F, Yuniastuti E, Bela B. HIV drug resistance after failure of 6 months first line therapy in a hospital: a case series. *Acta Med Indones*. 2019;51(3):253–57
7. Mziray SR, Kumburu H, Assey H, Sonda T, Mahande M, Msuya S et al. Pattern of acquired HIV-1 drug resistance mutations and predictors of virological failure in Moshi, Northern Tanzania. *PLoS One*. 2020;15(9): 1–19
8. Agegnuhu CD, Merid MW, Yenit MK. Incidence and predictors of virological failure among adult HIV patients on first line antiretroviral therapy in Amhara regional referral hospitals; Ethiopia: a retrospective follow-up study. *BMC Infect Dis*. 2020;20(460):1–14
9. Hassan AS, Nabwera HM, Mwaringa SM, Obonyo CA, Sanders EJ, de Wit TFR, et al. HIV-1 virologic failure and acquired among first line antiretroviral experienced adults at a rural HIV clinic in coastal Kenya: a cross-sectional study. *AIDS Res Ther*. 2014;11(9):1–12
10. World Health Organization (WHO). HIV drug resistance report 2019. Geneva: WHO. 2019.

11. Zuo L, Liu K, Liu H, Hu Y, Zhang Z, Qin J. Trend of HIV-1 drug resistance in china: a systematic review and metaanalysis of data accumulated over 17 years (2001-2017). *E Clin Med*. 2020;5(18):1–7
12. Zuo Z, Liang S, Sun X, Bussell S, Yan J, Kan W, et al. Drug resistance and virological failure among HIV-infected patients after a decade of antiretroviral treatment expansion in eight Province of China. *PLoS ONE*. 2016;11(12):1–13
13. Maruapula D, MacLeod I, Essex M, Leteane M, Moyo S, Seatla K, et al. Use of a mutation specific genotyping method to asses for HIV subtype c infected patients in Bostwana. *AAS Open Res*. 2021;7(3):1–20
14. Zou X, He J, Zheng J, Malmgren R, Li W, Wei X. Prevalence of acquired resistance mutations in antiretroviral-experiencing subjects from 2012 to 2017 in Hunan Province of central South China. *Virologia*. 2020;17(38): 1–9
15. Zhang Y, Ma L. Application of high throughput sequencing technology in HIV drug resistance detection. *Biosafety and health*. 2021;3(5):276–80
16. Nicholas S, Poulet E, Wolters L, Wapling J, Amoros I, Gueguen M, Schramm B, et al. Point of care viral load monitoring: outcomes from a decentralized HIV programme in Malawi. *J Int AIDS Soc*. 2019;22(8):1–8
17. Hutapea HML, Fitriana E, Natalia I, Wahyuni T, Adiningsih S, Widiyanti M. Gambaran kasus mutasi terkait resistensi antiretroviral pada orang dengan HIV-AIDS (ODHA) di tiga Kabupaten/kota di Provinsi Papua. *Balai Litbangkes Papua*. 2018;1–8
18. Santosa J, Utama IMS. Prevalensi resistensi ARV lini pertama pada pasien yang menerima pengobatan HAART di klinik HIV RSUP Sanglah Bali tahun 2014-2016. *E-Jurnal Medika*. 2017;6(10):42–46
19. Seitz R. Human immunodeficiency virus. *Transfus Med Hemother*. 2016;43:203–22

20. Goede A, Vulto A, Osterhaus A, Gruters R. Understanding HIV infection for the design of a therapeutic vaccine part I: epidemiology and pathogenesis of HIV infection. Elsevier. 2014;340:1–13
21. Musumeci D, Riccardi C, Montesarchio D. Q-Guadruplex forming oligonucleotides as anti HIV agents. *Molecules*. 2015;20:17511–32
22. Das S. Mechanism of lipid disorder in HIV infection: apolipoprotein-B kinetics, fat distribution, insulin resistance and adipocytokines in patients taking protease inhibitors or non-nucleoside reverse transcriptase inhibitors (e-theses repository). Birmingham; University of Birmingham; 2010.
23. HIV. Djoerban Z, Djauzi S. Dalam : Sudoyo AW, Setiyohadi B, Alwi I, Simadibrata M, Setiati S. *Buku Ajar Ilmu Penyakit Dalam*. Jakarta : Interna Publishing. 2014;2130– 32
24. Saag M, Gandhi R, Hoy J, Landovitz R, Thompson M, Smith D, et al. Antiretroviral drugs for treatment and prevention HIV infection in adults 2020 recommendation of the international antiviral society-USA panel. *JAMA*. 2020;1–18
25. World Health Organization (WHO). Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: Recommendations for a public health approach. Geneva: WHO. 3<sup>rd</sup> ed. 2019
26. Maarten G, Celum C, Lewin R. HIV infection:epidemiology, pathogenesis, treatment, and prevention. *Lancet*. 2014;384:258–71
27. Cuevas JM, Geller R, Garijo R, Lopez-aldeguer J, Sanjuan R. Extremely high mutation rate of HIV-1 in vivo. *PLOS Biol*. 2015;13(9):1–19
28. Masikini P, Mpondo BCT. HIV drug resistance mutations following poor adherence in HIV-infected patient: case report. *Clin Case Reports*. 2015;3(6):353–6
29. Sanjuan R, Domingo P. Mechanism of viral mutation. *Cell Mol Life Sci*. 2016;73(23):4433–48

30. Abram ME, Ferris A, Das K, Tuske S, Hughes S, Alvord G, et al. Mutations in HIV-1 reverse transcriptase affect the error made in single cycle of viral replication. *Virology*. 2014;13:7589–601
31. Wensing AM, Calvez V, Cecherini F, Charpentier C, Gunthard HF, Paredes R, et al. 2019 update of the drug resistance mutations in HIV-1. *Tropical Antiviral Medicine*. 2019;27(3):111–21
32. Arts, E.J. and Hazuda, D.J. HIV-1 antiretroviral drug therapy. *Cold Spring Harbor Perspectives in Medicine*. 2012;2(4):1–23
33. Hidayati N, Setyaningsih I, Pandanwangi S. Level of HIV/AIDS patient adherence to use of antiretroviral (ARV) drug in RSUD Gunung Jati Cirebon. *Jurnal Ilmiah Farmasi*. 2018;58–66
34. Pariaribo K, Hadisaputro S, Widjanarko B, Sofro M, Adi S. Faktor risiko yang mempengaruhi kepatuhan terapi antiretroviral (ARV) pada pasien HIV/AIDS di RSUD Abepura Jayapura. *Jurnal Epidemiologi Kesehatan Komunitas*. 2017;2(1):7–16
35. Larder B. Mechanism of HIV drug resistance. *AIDS*. 2001;15;1–7
36. Jordan M, Winsett J, Tiro A, Bau V, Berbara R, Rowley, et al. HIV drug resistance profiles and clinical outcomes in patients with viremia maintained at very low levels. *World Journal of AIDS*. 2013;3(2):71–8
37. Gunthard D, Calvez V, Paredes R, Pitlay D, Shafer R, Wensing A. Human immunodeficiency virus drug resistance : 2018 recommendations of the international antiviral society-US panel. *Clinical Infectious Diseases*. 2018;1–11
38. Vella S, Palmisano L. The global status of resistance to antiretroviral drugs. *Clinical Infectious Diseases*. 2005;41(4) :239–46
39. Ruiz FX, Arnold E. Evolving understanding of HIV-1 reverse transcriptase structure, function, inhibition, and resistance. *Current Opinion in Structural Biology*. 2020;61:113–23
40. Das K, Arnold E. HIV-1 reverse transcriptase and antiviral drug resistance part 1 of 2. *Current Opinion in Virology*. 2013;3(2):111–18
41. Clavel F. of HIV drug resistance : a primer. *New England Journal of Medicine*. 2004;350(10):1023–35

42. Ayitewala A, Kyeyune F, Alnembabazi P, Nabulime E, Kato C, Nankya I. Comparison of HIV drug resistance profiles across HIV-1 subtypes A and D for patients receiving a tenofovir-based and zidovudine-based first line regimens in Uganda. *AIDS Res Ther.*2020;17(2):1–9
43. Moyo S, Gaseitsiwe S, Zahralban-Steele, Maruapala D, Nkhisang T, Mokaleng B, et al. Low rates of nucleoside reverse transcriptase inhibitor and nonnucleoside reverse transcriptase inhibitor drug resistance in Botswana. *AIDS.* 2019;33(6):1073–82
44. Diallo K, Goutte M, Wainberg M. Molecular impact of the M184V mutation in human immunodeficiency virus type 1 reverse transcriptase. *Antimicrob Agents Chemother.* 2003;47(11):3377–83
45. Wendie TF, Workneh BD. Prevalence and predictors of virological failure among adults living with HIV in south wollo zone, northwestern ethiopia : a retrospective cohort study. *Pubmed.* 2020;12:393–402
46. Singh K, Marchand B, Kirby K, Sarafianos S, Michailidis E. Structural aspects of drug resistance and inhibition of HIV-1 reverse transcriptase. *Viruses.* 2010;2:606–18
47. Day JH, Grant AD, Fielding KL, Morris L, Molloi V, Charalambous S, et al. Does tuberculosis increase HIV load?. *J Inf Dis.* 2004;190:1677–74
48. Fenner L, Atkinson A, Boule A, Fox MP, Prozesky H, Zurcher K, et al. HIV viral load as an independent risk factor for tuberculosis in South Africa: collaborative analysis of cohort studies. *J. Int AIDS Soc.* 2017;20:213–27
49. Malagnino V, Cerva C, Maffongelli G, Teti E, Biland LF, Cesta N, et al. HbcAb seropositivity is correlated with poor HIV viremia control in an Italian cohort of HIV/HBV-coinfected patients on first-line therapy. *Scientific Reports.* 2019;9:11942.
50. Willis SJ, Cole SR, Westreich D, Edmonds A, Hurt CB, Albrecht S, et al. Chronic hepatitis C virus infection and subsequent HIV viral load among women with HIV initiating antiretroviral therapy. *AIDS.* 2018 ;32(5):653–61

51. Siraprapasiri P, Tharavichitkul E, Suntornpong N, Tovanabutra C, Meennuch E, Panboon P, et al. Effects of radiation therapy on immunological and virological status in HIV-infected cancer patients in Thailand: a multicenter prospective study. *J Med Assoc Thai.* 2016;99(2):9–16
52. Belgaumkar VA, Chavan RB, Suryataley PR, Salunke AS, Patil PP, Borade SM. Systemic lupus erythematosus in HIV: an insight into clinical implications and management. *Indian J Sex Transm Dis AIDS.* 2019;40(1):64–6
53. Barnabas R, Szpiro A, Rooyen H, Asimwe S, Pillay D, Joseph P, et al. Community based antiretroviral therapy versus standard clinic-based services for HIV in south africa and uganda: a randomised trial. *Lancet Glob Health.* 2020;8(10):e1245–315
54. Derache A, Hyoung S, Balamane M, White E, Israelski D, Klausner J, et al. HIV drug resistance mutations in proviral DNA from a community treatment program. *PLoS One.* 2015;1;1–14
55. Hegdahl H, Fyikesnes K, Sandey I. Sex differences in hiv prevalence persist over time: evidence from 18 countries in sub sahara africa. *Plos One.* 2016;1–17
56. Yuliandra Y, Nosa US, Raveinal, Almasdy D. Terapi antiretroviral pada pasien HIV/AIDS di RSUP M Djamil Padang: kajian sosiodemografi dan evaluasi obat. *Jurnal Sains Farmasi dan Klinis.* 2017;4(1):1–8
57. Girum T, Wasie A, Lentiro K, Muktar E, Worku A, Shegaze M, et al. Gender disparity in epidemiological trend of HIV/AIDS infection and treatment in Ethiopia. *Arch Public health.* 2018;76(51):1–10
58. Hutape HML, Kridaningsih TN, Prasetyo KH, Antwi MB. Viral load as a risk factor of reverse transcriptase inhibitor drug resistance mutation in antiretroviral treated people living with HIV/AIDS. *Universa Medicina.* 2021;40(3):243–53
59. Risher K, Cori A, Marston M, Calvert C, Crampin A, Newton R, et al. Age patterns of HIV incidence in eastern and southern Africa : a

modelling analysis of observational population based cohort studies. *Lancet*. 2021;8:429–39

60. Dong K, Ye L, Leng T, Liang S, Feng L, Yuan D. Prevalence of HIV-1 drug resistance among patients with antiretroviral therapy failure in Sichuan, China, 2010-2016. *J. Tohoku J. Exp. Med*. 2019;247:1–12
61. Seu L, Mulenga L, Mpanji S, Sikazwe L, Guffey M, Chi B. Characterization of HIV drug resistance mutations among patients failing first line antiretroviral therapy from a tertiary referral center in Lusaka, Zambia. *J Med. Virol*. 2015;87:1149–57
62. Tachbele E, Kyobe S, Kigozi E, Joloba M, Legesse M, Ameni G, et al. Virologic failures among antiretroviral treatment experienced human immunodeficiency virus patients in pastoralist region of Ethiopia. *Infect. Drug Resis*. 2021;14:4833–37
63. Misgena D. The pattern of immunologic and virologic response to highly active antiretroviral treatment (HAART) : does success bring further challenges. *Ethiop. J. Health Dev*. 2011;25(1):61–70
64. Widiyanti M, Fitriana E, Natalia E, Wike I. Identification of antiretroviral mutation in protease and reverse transcriptase inhibitor in human immunodeficiency virus-1 of HIV/AIDS patients in Mimika Regency, Papua. *Folia Medica Indonesiana*. 2017;53(1):56–63
65. Chaiyasin N, Sungkanuparph S. rate of CD4 decline and factors associated with rapid CD4 decline in asymptomatic HIV infected patients. *J. Int Assoc Provid AIDS Care*. 2015;1–4
66. Miti S, Handema R, Mulenga L, Mwansa J, Abrams E, Siwingwa M, et al. Prevalence and characteristics of HIV drug resistance among antiretroviral treatment (ART) experienced adolescents an young adults living with HIV in Ndola, Zambia. *PLoS One*. 2020;1–15
67. Etta E, Mavhandu I, Manhaeve C, Rekosh D, Hammrskjold M, Tebit D. High level of HIV-1 drug resistance mutations in patients with unsuppressed viral loads in rural northern South Africa. *AIDS Res Ther*. 2017;14(36):1–12

68. Chendi B, Assoumoi M, Jacobs G, Yekwa E, Eyoh A, Ikomey G, et al. rate of viral load change and adherence of HIV adult patients treated with Efavirenz or Nevirapine antiretroviral regimens at 24 and 48 weeks in Younde, Cameroon : a longitudinal cohort study. *BMC Infect Dis.* 2019;19:1–8
69. Atnafu G, Moges N, Wubie M, Gedif G. Incidence and predictors of viral load suppression after enhanced adherence counseling among HIV positive adults in West Gojjam Zone, Amhara Region, Ethiopia. *Infect Drug Resist.* 2022;15:261–74
70. Mocroft A, Ledergerber B, Staszewski S, Viard P, Chiesi A, Murphy M, et al. Time to virological failure of 3 classes of antiretrovirals after initiation on highly active antiretroviral therapy: results from the EuroSIDA study group. *J Infect Dis.* 2004;190:1947–56
71. Novitsky V, Essex M. Using HIV viral load to guide treatment for prevention interventions. *Curr Opin HIV AIDS.* 2012; 7(2):117–24
72. Makwaga O, Adhiambo M, Maulama D, Muoma J, Mwau M. HIV Drug resistant mutations in relation to virological failure among adults in Busia county, Kenya. *Afr. J. Health.* 2020;33(4):56–71
73. Assoumou L, Descamps D, Yerly S, Santos G, Marcelin A, Ruffault A, et al. Prevalence of HIV drug resistance in treated patients with viral load > 50 copies/mL in 2009: a French nationwide study. *J Antimicrob Chemother.* 2013;5(10):1400–05
74. Pingarilho M, Pimentel V, Fernandes S, Miranda M, Abecasis A, Camacho R, et al. Increasing prevalence of HIV-1 transmitted drug resistance in Portugal: implications for first line treatment recommendations. *Viruses.* 2020;12:1–15